<DOC>
	<DOCNO>NCT03002935</DOCNO>
	<brief_summary>This open-label , Phase I study bioavailability safety BPM31510 administer orally healthy subject dose 3 time daily 14 day . The last study dose administer Day 15 ( one morning dose ) . The study consist 25 subject .</brief_summary>
	<brief_title>A Safety Study Orally Administered BPM31510 Healthy Subjects</brief_title>
	<detailed_description>Study subject admit clinic Day -1 . All subject self-administer Day 1 dos study drug supervision clinic staff . Doses 3200 mg administer three time per day meal . Dosing continue additional 14 day outpatient basis Day 5 morning dose last study dose Day 15 administer clinic ( one morning dose , give Day 15 ) . On Days 1 , 2 , 5 15 , pharmacokinetic ( PK ) pharmacodynamics ( PD ) sample perform 30 minute prior first dose , 0.5 , 1 , 2 , 4 hour first dose visit additional PK draw Day 1 0.5 , 1 , 2 , 4 second dose . Urine PK/PD collect pre-dose Day 1 , Day 2 , Day 5 Day 15 . At visit ( Days 1 , 2 , 5 final dose Day 15 ) , sample collect chemistry , Complete Blood Count ( CBC ) , International normalize ratio ( INR ) , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) , cholesterol , low density lipoprotein ( LDL ) , high density lipoprotein ( HDL ) , vitamin K level . Blood sample PK/PD collect 30 minute prior morning dose Day 5 Day 15 also 0.5 , 1 , 2 , 4 hour dose . Lab sample ( chemistry , etc . ) , also drawn time first PK/PD draw Day 5 Day 15 . A phone interview conduct few 25 day 35 day last dose Day 15 collect information concomitant medication adverse event Graded use Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.0 .</detailed_description>
	<mesh_term>Coenzyme Q10</mesh_term>
	<criteria>Men woman , age &gt; 18 year Body mass index ( BMI ) ≥19 ≤30 Good health condition without significant illness , judgment legally qualify professional , accord follow evaluation : medical history , physical examination , vital sign , electrocardiogram ( ECG ) , screen baseline hematology clinical chemistry measure . Subjects child bear potential must agree use one accept method contraception ( list ) trial ( include screen period prior receive trial medication ) , least return menstruation stop trial medication . condom ( male female ) spermicide diaphragm cervical cap spermicide Intrauterine device ( IUD ) hormonal contraception condom ( male female ) Female subject must negative pregnancy test result screen Day1 PT/PTT/INR within normal limit Vitamin K level within normal limit Capable understand comply protocol signing informed consent Pregnant lactate female subject Known hypersensitivity study drug ( Coenzyme Q10 ) compound chemically related History presence hepatic gastrointestinal illness , condition interferes drug 's absorption , distribution , excretion metabolism History hepatic , renal , pulmonary , gastrointestinal , epileptic , hematologic psychiatric illness Hypotension hypertension etiologic need pharmacologic treatment History exist coagulopathy History myocardial infarction , angina , and/or heart insufficiency Nonrecommended electrocardiographic finding , accord investigator criterion Results laboratory exam normal range unless consider clinically irrelevant investigator Subject smoker Subject ingest 5 cup coffee tea day History alcohol drug abuse History serious adverse reaction hypersensitivity drug Ongoing regular use oral prescription drug , exception oral contraceptive Hospitalization reason within 8 week prior study dose Participation experimental study ingest experimental drug within 30 day precede study Donation loss 450 mL blood within 3 month prior Screening/Baseline Subject consume alcohol 48 hour prior baseline measurement study Subject report history human immunodeficiency virus Currently use coenzyme Q10 overthecounter product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>